Intravenous (IV) Iron Drugs

Intravenous (IV) Iron Drugs

Global Intravenous (IV) Iron Drugs Market to Reach US$4.8 Billion by 2030

The global market for Intravenous (IV) Iron Drugs estimated at US$2.9 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2023-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Iron Dextran segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 10.8% CAGR

The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$1.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Intravenous (IV) Iron Drugs Market - Key Trends & Drivers Summarized

Intravenous (IV) iron drugs are essential treatments used primarily for addressing iron deficiency anemia, a condition where the body lacks sufficient iron to produce healthy red blood cells. These drugs are administered directly into the bloodstream, allowing for quick and efficient absorption, especially in patients who cannot tolerate or adequately absorb oral iron supplements. IV iron therapy is crucial for patients with chronic kidney disease, inflammatory bowel disease, heart failure, and those undergoing chemotherapy, as these conditions often result in significant iron loss or hinder the absorption of iron. Various formulations of IV iron, such as iron sucrose, ferric carboxymaltose, and iron dextran, have been developed to optimize their efficacy and safety, minimizing potential side effects like allergic reactions or anaphylaxis. The advancement in these formulations has made it possible to deliver higher doses in a single session, improving patient compliance and outcomes.

The growth in the intravenous (IV) iron drugs market is driven by several factors, including technological advancements in drug formulations, expanding indications for IV iron therapy, and increasing awareness among healthcare providers and patients about the benefits of IV iron. The development of newer, safer formulations that allow for higher doses and quicker administration has significantly enhanced the appeal of IV iron therapies. Additionally, the rising prevalence of chronic diseases such as chronic kidney disease, cancer, and heart failure, which are often associated with iron deficiency, has created a higher demand for effective iron supplementation methods. The expanding applications of IV iron in managing these conditions, coupled with improved diagnostic capabilities, have also contributed to market growth. Furthermore, the growing emphasis on outpatient care and the reduction of hospital stay durations are influencing the adoption of IV iron treatments, as they align with the broader healthcare trend towards more efficient and patient-friendly therapeutic options.

The global intravenous iron drugs market, therefore, is forecast to witness a steady growth, driven by the increase in aging population, growing life expectancy rate, growing incidence of CKD, and rise in number of ESRD patients. Other factors driving growth include increasing healthcare expenditure, rising urbanization, and favorable guidelines laid down by healthcare organizations. Furthermore, the market is also witnessing rapid transition in terms of demand from traditional dextran to non-dextran intravenous iron drugs. Non-dextran intravenous iron drug offer higher advantageous over dextran intravenous iron drugs in terms of delivering higher doses of infusing iron in a shorter time period. Additionally, the non-dextran based drugs are capable of addressing various challenges, such as safety, intolerance, dosing, and compliance associated with traditional iron therapies.

 

 

 

 

 

 

Select Competitors (Total 33 Featured) -

• AbbVie Inc (AbbVie)
• Akebia Therapeutics, Inc.
• American Regent, Inc.
• Covis Pharma GmbH.
• Daiichi Sankyo Company, Ltd.
• Galenica Group
• Iron4u Aps
• NIPPON SHINYAKU CO., LTD.
• Pharmacosmos A/S
• Rockwell Medical, Inc.
• Sanofi S.A.
• Shield Therapeutics Plc
• Vifor Pharma Management Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.